Tier 2 — strong

A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects

Serena A Heinz, Dru A Henson, David C Nieman, Melanie D Austin, Fuxia Jin
The British journal of nutrition 2010 104(6):849

Bibliography

PubMed
PMID 20500927
DOI
10.1017/S000711451000156X
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled immune-function analysis
ModelHuman intervention research
Sample120 women; smaller subsets underwent individual immune assays
InterventionQuercetin 500 or 1,000 mg/day or placebo
Duration12 weeks
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2010, this source examined immunity and respiratory health. Design: Randomized double-blind placebo-controlled immune-function analysis. Sample/model: 120 women; smaller subsets underwent individual immune assays. The exposure or intervention was Quercetin 500 or 1,000 mg/day or placebo. Follow-up or treatment period: 12 weeks.

Natural killer-cell activity, granulocyte function, leukocyte subsets, and measured cytokines did not improve.

Subset analyses from a larger community supplementation program. Higher plasma exposure did not demonstrate enhanced innate immunity.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Natural killer-cell activity, granulocyte function, leukocyte subsets, and measured cytokines did not improve.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Quercetin 500 or 1,000 mg/day or placebo; 12 weeks.

What this study can and cannot tell us

  • Subset analyses from a larger community supplementation program. Higher plasma exposure did not demonstrate enhanced innate immunity.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Influence of quercetin supplementation on disease risk factors in community-dwelling adults
Amy M Knab et al. · Journal of the American Dietetic Association · 2011
Tier 2
Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial
Serena A Heinz et al. · Pharmacological research · 2010
Tier 2
The variable plasma quercetin response to 12-week quercetin supplementation in humans
F Jin et al. · European journal of clinical nutrition · 2010
Tier 2
Quercetin with vitamin C and niacin does not affect body mass or composition
Amy M Knab et al. · Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2011
Tier 2
The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial
Joshua J Broman-Fulks et al. · Therapeutic advances in psychopharmacology · 2012
Tier 2
Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults
Lynn Cialdella-Kam et al. · The British journal of nutrition · 2013

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology